<DOC>
	<DOCNO>NCT00149058</DOCNO>
	<brief_summary>Erythropoietin ( EPO ) naturally occur hormone regulate body 's response lack oxygen control number red cell blood . Recent study animal show EPO protective effect organ heart brain injured lack oxygen due reduce blood supply . We wish test idea give patient , heart attack , injection EPO reduce size heart attack .</brief_summary>
	<brief_title>Erythropoietin Acute Myocardial Infarction</brief_title>
	<detailed_description>We wish perform randomised double-blind , placebo-controlled clinical trial examine effect EPO give time primary angioplasty acute myocardial infarction ( MI ) myocardial infarct size . In trial null hypothesis effect EPO myocardial infarct size , alternative hypothesis EPO reduce myocardial infarct size . 124 subject acute ST-elevation MI fulfil inclusion/exclusion criterion give inform consent participate study recruit patient referred cardiac catheterisation laboratory Hammersmith Hospital King 's College Hospital . Subjects undergo primary percutaneous coronary angioplasty ( primary PCI ) accord standard clinical protocol . Subjects randomise either placebo EPO time primary PCI . EPO give bolus 12ml contain 33,000U 30 min via peripheral vein follow infusion 24ml contain 67,000 U 12 hour . Placebo identical EPO without active ingredient . After PCI subject receive standard care coronary care unit . An additional 20ml blood take day time routine clinical venesection storage subject gadolinium enhance cardiovascular magnetic resonance ( CMR ) perform discharge evaluate infarct size . Follow-up perform 30 day ( clinical , ECG 20ml blood sample ) 90 day ( clinical , ECG CMR scan blood sample ) . The study end 90 day patient continue standard clinical care direction consultant cardiologist . CMR perform Robert Steiner MR Unit/Imaging Department , Hammersmith Hospital use 1.5 tesla scanner accord standard protocol . Each scan last 1h information collect tissue characteristic , leave ventricular function , wall motion abnormality , myocardial perfusion . Myocardial infarct detect late contrast gadolinium enhancement . Gadolinium use dos 0.2mmol/kg safe incidence mild transient side effect include headache nausea ~1 % . Scans perform continuous ECG monitoring doctor least 1 person present . Resuscitation facility available time MRI facility cover experience 24 hour day cardiac arrest team .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female &gt; 18 year age Weight 50 kg 120 kg Suspected his/her firstdocumented STEMI Symptoms ischemia &gt; 20 min &lt; 6h prior PCI Either 1mm ST elevation least two contiguous limb lead &gt; 2mm ST elevation 2 contiguous chest lead Primary PCI occur within 8h onset symptom Women childbearing potential must negative pregnancy test Contraindications MRI scan History ECG evidence previous STEMI Cardiogenic shock NYHA class IIIIV heart failure LBBB AF ECG ; 6.Major trauma , major surgery , eye , spinal cord , brain surgery within last 3 month Significant hepatic disturbance Chronic renal impairment ( Creatinine &gt; 200Âµmol/L ) Stroke TIA &lt; 6 month Pregnancy breastfeed Dependence alcohol DOA Significant psychiatric/neurologic disease would prevent adherence requirement protocol Significant immunocompromise ( include , limited AIDS immunesuppressive therapy Current treatment human recombinant erythropoietin Current hemodialysis peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>primary angioplasty</keyword>
</DOC>